Loading
Metastatic Non Small Cell Lung Cancer / Advanced Non Small Cell Lung Cancer / MRTX849 · Phase 3 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registration comparing MRTX849 (adagrasib), a KRAS G12C inhibitor, against docetaxel in previously treated patients with metastatic NSCLC harbouring KRAS G12C mutations. No results are reported in this registry record; the study is actively recruiting or recently completed but outcomes remain unpublished.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer; age from 18 Years. Intervention: MRTX849. Compared with: Docetaxel — Active Comparator. n = 453. 380 sites across 24 countries.
This is a Phase 3 trial registration comparing MRTX849 (adagrasib), a KRAS G12C inhibitor, against docetaxel in previously treated patients with metastatic NSCLC harbouring KRAS G12C mutations. No results are reported in this registry record; the study is actively recruiting or recently completed but outcomes remain unpublished.
This is a registry record with no results posted; no efficacy, safety, or efficacy data are available. No secondary outcomes, safety endpoints, or subgroup analyses are described in this registry entry.
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned or ongoing Phase 3 study with no results posted; efficacy and safety data are not yet available in this source.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04685135). This is a study registration, not published results. Lead sponsor: Mirati Therapeutics Inc.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 453 participants (ACTUAL). Conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer. Interventions: DRUG: MRTX849; DRUG: Docetaxel. Primary outcome measures: Progression-Free Survival (PFS) as Per Blinded Independent Central Review , From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks). Brief summary: This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.